The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome

ConditionsTako Tsubo Cardiomyopathy Microvascular Dysfunction CD34+ Stem Cells Heart Failure Cardiac Contractility Recovery

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorUniversity Medical Centre Ljubljana

About this trial

The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.

Eligibility criteria

Qualifiers

Minimum age 18 years

Established TTS per InterTak registry criteria

Signed consent form

Disqualifiers

Patients under the age of 18 years

Ischemic heart disease with at least one complete total occlusion

Other concurrent cardiomyopathies

Active infectious myocarditis

Trial design

Treatments tested in this trial

Not listed

Trial groups

40 Participants

are grouped into 1 trial group

Sponsors and collaborators

University Medical Centre Ljubljana

Lead sponsor

Source ClinicalTrials.gov